Another question was whether a combination approach of ancistrocladinium A with the clinically approved anti-MM agent panobinostat, an HDAC inhibitor [8], would result in enhanced cell death in MM cell lines when using EC25 doses of both compounds for 3 d. Here, HDAC9 is linked to Miyoshi myopathy.